

γ-LACTAM ANALOGUES OF CARBAPENICILLANIC ACIDS

JACK E. BALDWIN*, ROBERT M. ADLINGTON, RICHARD H. JONES,
CHRISTOPHER J. SCHOFIELD AND CONSTANTINE ZARACOSTAS

The Dyson Perrins Laboratory, University of Oxford, South Parks Road,
Oxford OX1 3QY, U.K.

and COLIN W. GREENGRASS


Pfizer Central Research, Sandwich, Kent CT13 9NJ, U.K.

(Received in UK 23 May 1986)


Abstract - The syntheses and biological activities of the γ-lactam analogues (*endo*-25), (*exo*-25) and (26) of carbapenicillanic acids are described. The strategy employed for the synthesis of 26 effected construction of a γ-lactam onto a preformed azetidene, followed by direct amination of the lactam enolate (20) with diphenylphosphinoyl-hydroxylamine. X-ray crystallographic studies demonstrated that the analogues bore a strong morphological resemblance to carbapenicillanic acids; however, they were shown to be devoid of antibacterial and beta-lactamase inhibitory activity.¹

Since the recent discoveries of the non-traditional beta-lactam antibiotics,² it now appears that the minimum structural requirement for a member of this class of antibiotic to show antibacterial activity is a suitably activated beta-lactam ring. In an attempt to develop a novel class of antibiotics we recently reported the synthesis of the beta-lactam analogue (1) and demonstrated it was devoid of both antibacterial and beta-lactamase inhibitory activity.^{3,4} X-Ray crystallographic studies showed that the sum of the bond angles about the nitrogen atom⁵ of 2 was 356°.


Molecular modelling studies indicated that fused γ-lactam-azetidene analogues, such as 3, would have similar pyramidal distortions to those observed for the lactam-nitrogen in penicillins. As it has been hypothesised that the degree of pyramidal distortion of the lactam-nitrogen of beta-lactam antibiotics, as in 4, is related to antibacterial activity⁶ we undertook a synthesis of the analogue, 5.




1 R=PhOCH₂CONH, R¹=H
2 R=OH, R¹=Me



3




4



5




Two possible strategies to the target (5), a and b were explored (Scheme 1). In initial studies we were unable to construct an azetidene onto a preformed lactam as in a, however the alternative b was successful.




Scheme 1




Thus, bromination of glutaric anhydride gave crude α,α' -dibromoglutaric anhydride (**6**),⁷ which was ring opened with formic acid. The crystalline α,α' -dibromoglutaric acid (**7**) which resulted, was reconverted into pure **6**, with a *dl:meso* ratio of 3:1⁸, by refluxing in acetyl chloride. Solvolysis of **6** (MeOH, Na₂CO₃) gave the monomethyl ester (**8**). Formation of acid chloride (**9**) (oxalyl chloride, *N,N*-dimethylformamide) followed by reaction with *t*-butanol and pyridine at -15°C, gave diester (**10**) (diastereomeric ratio 3:2). Formation of the diester (**10**) at 20°C gave a reversal in the diastereomeric ratio, such that the previously minor isomer became predominant (4:1), in accordance with proposals that the base catalysed solvolysis of acid chlorides can proceed via two distinct mechanisms.⁹

Cromwell has reported the preparation of azetidines in good yield by the reaction of benzylamine with 2,4-dibromobutanoates.¹⁰ Thus, reaction of the diester (**10**) with 3 equivalents of benzylamine in dimethylformamide at 80°C gave the diastereomeric azetidines (*cis*-**11**) and (*trans*-**11**) (84% from **6**, *trans:cis* 3:2). Separation of the diastereomers was achieved by careful chromatography, however a more facile separation of the *cis* and *trans* series was produced by reduction (NaBH₄) to give *cis*-**12** and *trans*-**12** (80%), from which *cis*-**12** could be fractionally crystallised. The structure of *cis*-**12** was unequivocally established by X-ray crystallographic analysis (Figure 1).




**6****7** R, R¹=OH**8** R=OH, R¹=OMe**9** R=Cl, R¹=OMe**10** R=O^tBu, R¹=OMe**11** R=CH₂Ph, R¹=CO₂Me**12** R=CH₂Ph, R¹=CH₂OH**13** R=H, R¹=CH₂OH**14** R=CO₂CH₂Ph, R¹=CH₂OH

Hydrogenation of the mother liquors (containing almost pure *trans*-**12**), followed by reprotection of the resultant amine (*trans*-**13**) gave the *N*-benzyloxycarbonylazetidine (*trans*-**14**), which was recrystallised to homogeneity. A similar sequence applied to pure *cis*-**12** gave *cis*-**14** as an oil.



Figure 1. Structure of *cis*-**12**

151617[Z=PhCH₂OCO-][PNB=O₂NC₆H₄CH₂-]

The individual alcohols (trans-14) and (cis-14) were converted into the bicyclic- γ -lactams (exo-19) and (endo-19) by standard methodologies. Thus, Moffatt oxidation of cis-14 gave the aldehyde (cis-15) which was reacted with (triphenylphosphoranylidene)acetic acid *p*-nitrobenzyl ester to give cis-16, as a mixture of olefins. Similarly, aldehyde trans-15 gave trans-16, though in this case only the *E* isomer was isolated. Reduction of cis-16 using 10% palladium on carbon as catalyst led to cleavage of the azetidine ring.¹¹ However, a two stage reduction using Wilkinson's catalyst for the initial conversion of cis-16 to cis-17, followed by hydrogenation using palladium on carbon gave the amino acid (cis-18). Cyclisation with 2,2'-dipyridyldisulphide and triphenylphosphine¹² gave the bicyclic γ -lactam (endo-19) (55% from cis-14). An analogous sequence applied to trans-16 gave the bicyclic lactam, (exo-19) (58% from trans-14). The structures as endo- and exo-19 were unequivocally established by X-ray crystallographic analysis.

18endo-19, R=*t*Buendo-23, R=Hendo-25, R=Kendo-27, R=Meexo-19, R=*t*Buexo-23, R=Hexo-25, R=Kexo-27, R=Me

Reaction of exo-19 with lithium hexamethyldisilazide gave the monoanion (20) which was quenched with *O*-(diphenylphosphinoyl)hydroxylamine¹³ to give the 3-aminobicyclic- γ -lactam (21), which was coupled with phenoxyacetic acid to give 22 (40% from exo-19). X-Ray crystallographic analysis (Figure 2) demonstrated that the amine function was introduced trans- to the *t*-butyl ester (trans:cis addition ca > 10:1), probably indicating that the steric bulk of the *t*-butyl group overrode that of the convex nature of the bicyclic γ -lactam (20) during the amination reaction.

2021 R=H, R'=*t*Bu22 R=PhOCH₂CO, R'=*t*Bu24 R=PhOCH₂CO, R'=H26 R=PhOCH₂CO, R'=K29 R=PhOCH₂CO, R'=K

The analogues (exo-19), (endo-19) and (22) were deprotected (trifluoroacetic acid) to give exo-23, endo-23 and 24 respectively, then dissolved in pH 7.6 phosphate buffer to give the respective carboxylates (exo-25), (endo-25) and (26). These were shown to be stable in phosphate buffer for greater than 12 hours (by ^1H NMR, 300MHz) and by subsequent re-esterification to their corresponding methyl esters (exo-27), (endo-27) and (29).






Figure 2. Structure of 22

The X-ray crystallographic studies demonstrated that in common with antibacterial bicyclic β -lactams, compounds endo-19, exo-19 and 22 have pyramidal lactam-nitrogen atoms. The degree of pyramidalicity was of a similar order to that of the penicillins, the sum of the angles⁵ around nitrogen for endo-19, exo-19, 22 and penicillin G being 334, 330, 326 and 337° respectively. However, Cohen has pointed out that a more significant parameter for antibacterial activity may be the interatomic distance between the β -lactam oxygen and the carboxylate carbon, values of between 3.0 and 3.9 Å being observed for active compounds.¹⁴ The analogous distances for exo-19 and 22 were both 4.1 Å.

The analogues (endo-25), (exo-25) and (26) were tested against a representative panel of Gram positive and Gram negative organisms (Pfizer, Sandwich). All were found to be inactive up to a concentration of 0.1mg ml⁻¹. In separate tests of the three analogues for β -lactamase inhibitory activity against β -lactamase I (from Bacillus cereus), no significant activity was detected.



28



30

Recently, the preparation and biological evaluation of the bicyclic azete (28)¹⁵ and the γ -lactam analogue of the penems (30)¹⁶ have been reported. These compounds have been shown to possess antibacterial activity against both gram positive and gram negative bacteria.

EXPERIMENTAL

Standard laboratory practice as previously described¹⁷ was observed. Melting points were recorded on a Büchi 510 apparatus and are uncorrected. Infra red spectra were recorded on a Perkin-Elmer Model 681 spectrophotometer. All ¹H NMR spectra were recorded at 300MHz on a Bruker WH 300 NMR spectrometer using deuteriochloroform as solvent referenced to residual CHCl₃ = 7.27 p.p.m. unless otherwise stated. Coupling constants, *J*, were recorded to the nearest (\pm) 0.5Hz. All ¹³C NMR spectra were recorded at 62.85MHz or 75.4MHz using either a Bruker AM 250 or Bruker WH 300 spectrometer respectively, with deuteriochloroform as solvent referenced to CDCl₃ = 77.00 p.p.m. unless otherwise stated. Only selected I.R. and ¹³C NMR signals are assigned. Mass spectra in the electron impact (E.I.) or chemical ionisation (C.I.) modes were recorded on a VG Micromass 16F spectrometer. Samples requiring desorption chemical ionisation (D.C.I.) and accurate mass measurement (E.I.) were run on VG Micromass 30F or ZAB IF spectrometers.

Preparation of α, α' -Dibromoglutaric acid methyl, *t*-butyl ester (10).

The following four reactions were performed without purification of the intermediates. An overall yield is given.

 α, α' -Dibromoglutaric anhydride (6).

A solution of **7** (50.0g, 172 mmol) in acetyl chloride (65 ml) was refluxed until the solid had dissolved and evolution of gas had ceased (ca 2.5 hours). The excess acetyl chloride was removed *in vacuo* to give crude **6**, as an oil (dl:meso, ca 3:1). ν_{\max} (film) 1823 s, 1782 s, 1242 m, 1035 s, 688 m and 615 s cm⁻¹; δ H (meso) 2.68-2.98(1H, m, CH₂), 3.11-3.19(1H, m, CH₂), 4.78-4.89(2H, m, CHBr); (dl) 2.86(2H, t, *J* 6Hz, CH₂), 4.91(2H, t, *J* 6Hz, CHBr); m/e (NH₃, C.I.) 275/273/271 (M⁺+1), 274/272/270 (M⁺), 149(17), 147(17), 122(80), 120(80), 39(100).

 α, α' -Dibromoglutaric acid monomethyl ester (8).

To the solution of crude **6** in dichloromethane at 0°C was added, dropwise (over 10 minutes), a saturated solution of sodium carbonate in dry methanol (100 ml). The solution was then allowed to warm to room temperature (ca 30 minutes) and all volatiles were removed *in vacuo* (30°C, 1mm Hg), to give crude **8** as an oil (diastereomer ratio, ca 3:1). ν_{\max} (film) 3220 b, 1740 s, 1430 s, 1280 b, 1165 s. δ H (major) 2.58-2.79(2H, m, CH₂), 3.82(3H, s, CH₃), 4.48-4.62(2H, m, CHBr), 10.1 [2H, bs, OH of both (major) and (minor)]; (minor): 2.58-2.79 [1H, m, CH₂, obscured by CH₂ of (major)], 2.81-2.96(1H, m, CH₂), 3.85(3H, s, CH₃), 4.38-4.45(2H, m, CHBr), 10.1(2H, bs, OH); m/e (E.I.) 305/303/301 (M⁺-1), 289/287/285 (M⁺-OH), 288/286/284 (M⁺-H₂O), 225/223 (M⁺-Br), 163(50), 99(100).

 α, α' -Dibromoglutaric monoacid chloride monomethyl ester (9).

To the solution of crude **8** (as obtained from the previous reaction) and oxalyl chloride (25.0 g, 195 mmol) in dichloromethane (125 ml) was added pyridine (ca 0.5 ml). The solution was stirred until gas evolution had ceased (ca 3 hours). All volatiles were removed *in vacuo* (30°C, 1mm Hg) to give crude **9** as a colourless oil (diastereomer ratio, ca 3:1); ν_{\max} (film) 1784 s, 1745 s, 1440 m, 1280 m, and 1164 m; δ H (major): 2.59-2.85(2H, m, CH₂), 3.80(3H, s, CH₃), 4.49(1H, dd, *J* 10.4Hz, CHCO₂), 4.80(1H, dd, *J* 10.4Hz, CHCOCl); (minor): 2.59-2.65 [1H, m, CH₂, obscured by CH₂ of (major)], 2.89-3.00(1H, m, CH₂), 3.78(3H, s, CH₃), 4.37-4.42(1H, m, CHCO₂), 4.67-4.72(1H, m, CHCOCl); m/e (NH₃, C.I.) 289/287/285 (M⁺-COCl), 207(10), 205(10), 179(26), 177(26), 151(17), 149(17), 39(100).

 α, α' -Dibromoglutaric acid methyl, *t*-butyl ester (10).

A stirred solution of crude **9** from the previous reaction in dichloromethane (150 ml) and *t*-butanol (50 ml) was cooled to -25°C. Pyridine (13.8 ml, 0.17 mol) in dichloromethane (30 ml) was then added dropwise over 15 minutes, whilst maintaining the temperature of the reaction mixture below -15°C. After the addition was complete the reaction mixture was allowed to warm to room temperature and was stirred for a further 1 hour. The solution was then washed (1N hydrochloric acid, aqueous saturated sodium bicarbonate and brine, dried (Na₂SO₄), filtered and evaporated to dryness to give crude **10** [59.4 g, 90% from **7** (50 g)] (diastereomer ratio, ca 3:2); ν_{\max} (film) 2990 m, 1740 s, 1440 m, 1372 s, 1280 b and 1151 cm⁻¹; δ H (major): 1.44(9H, s, *t*-Bu), 2.43-2.65(2H, m, CH₂), 3.76(3H, s, CH₃), 4.29-4.43(2H, m, CHBr); (minor): 1.49(9H, s, *t*-Bu), 2.50-2.60(1H, m, CH₂), 2.70-2.74(1H, m, CH₂), 3.77(3H, s, CH₃), 4.22(1H, t, *J* 7.5Hz, CHBr), 4.45-4.53(1H, m, CHBr); m/e (E.I.) 289/287/285 (M⁺-C₄H₉), 179(3), 177(3), 57(100).

1-Benzyl-2-(carboxylic acid *t*-butyl ester)-4-carboxylic acid methyl ester)azetidine (11).

A solution of the crude diester (10) (56.4 g, 157 mmol) in dimethylformamide (200 ml) containing benzylamine (50.5 g, 471 mmol) was heated at 80°C for 2 hours. All volatiles were removed *in vacuo* (35°C, 0.1mm Hg) and the residue dissolved in ethyl acetate (100 ml). The organic solution was washed (1N hydrochloric acid, aqueous saturated sodium bicarbonate and brine), dried (Na₂SO₄), filtered and evaporated to dryness to give the title compound (11) (42.6 g, 89%) (trans-11:cis-11, ca 3:2). A small amount (20 mg) of the mixture was chromatographed [P.L.C., two elutions with ethyl acetate/hexane, 1:19] to give the isolated azetidines (trans-11) and (cis-11) as colourless oils. For trans-11: t.l.c. [2 x ethyl acetate/hexane, 1:19] R_f 0.5; ν_{\max} 1740 s, 1735 s, 1370 m and 1156 m cm⁻¹; δ H 1.35(9H, s, *t*-Bu), 2.39(2H, ca t, *J* 7Hz, 3-H), 3.56(3H, s, OCH₃), 3.82(2H, s, NCH₂), 4.02(1H, ca t, *J* 7Hz, CHN), 4.13(1H, ca t, *J* 7Hz, CHN), 7.16-7.32(5H, m, Ph); m/e (F.D.) 305 (M⁺) [Found M⁺ 305.1627. C₁₁H₁₂N₂O₄ requires 305.1626]. For cis-11: t.l.c. [2 x ethyl acetate/hexane, 1:19] R_f 0.45; ν_{\max} 1740 s, 1370 m, 1230 s and 1158 cm⁻¹; δ H 1.36(9H, s, *t*-Bu), 2.22-2.50(2H, m, 3-H), 3.48(1H, ca t, *J* 8Hz, CHN), 3.56(1H, ca t, *J* 8Hz, CHN), 3.61(3H, s, OCH₃), 3.65, 3.85(2H, ABq, *J* 13Hz, NCH₂), 7.20-7.37(5H, m, Ph); m/e (F.D.) 305 (M⁺) [Found 305.1627. C₁₁H₁₂N₂O₄ requires 305.1626].

1-Benzyl-2-(carboxylic acid t-butyl ester)-4-(hydroxymethyl)azetidide (12).

The crude 11 (10.0 g, 32.8 mmol) was reduced with sodium borohydride (10.0 g, 263 mmol) at 0°C in methanol (150 ml) for 3h. The excess borohydride was destroyed with aqueous ammonium chloride, after which work up as described for the preparation of 11 gave crude 12 (5.85 g, 80%) (trans:cis, ca 3:2). Fractional crystallisation (at -30°C from hexane) gave pure cis-12 leaving trans-12 in the mother liquors. A small amount of trans-12 was purified for spectroscopic analysis by chromatography [P.L.C., ether/hexane, 1:1]. For trans-12: t.l.c. [ether/hexane, 1:1] Rf 0.4; ν_{\max} 3420 b, 2980 m, 1736 s, 1368 m and 1153 s cm^{-1} ; δ_{H} 1.38(9H, s, t-Bu), 1.94-2.20(1H, m, 3-H), 2.36(1H, ca dt, J 11, 8Hz, 3-H), 2.40(1H, b, OH), 3.17(2H, d, J 3Hz, CH_2O), 3.66, 3.88 (2H, ABq, J 13Hz, NCH_2), 3.87(1H, dd, J 8, 3Hz, 2-H), 3.89-3.96(1H, m, 4-H), 7.13-7.23(5H, m, Ph); m/e (NH_3 , C.I.) 278(35, $\text{M}^+ + 1$), 222(45), 176(81), 91(100). For cis-12: m.p. 93-95°C (from hexane); ν_{\max} 3420 b, 1717 s, 1745 s and 1702 s, 1360 s cm^{-1} ; δ_{H} 1.30(9H, s, t-Bu), 2.11-2.23 (2H, m, 3-H), 2.90(1H, b, OH), 3.09-3.20(2H, bm, CH_2O), 3.23-3.33(1H, m, 4-H), 3.47(1H, t, J 8.5Hz, 2-H), 3.58, 3.71(2H, ABq, J 12.5Hz, NCH_2), 7.16-7.23(5H, m, Ph); m/e (NH_3 , C.I.) 278(100, M^+), 222(20), 176(40), 91(13) [Found C, 69.00; H, 8.34; N, 4.89. $\text{C}_{14}\text{H}_{23}\text{NO}_4$ requires C, 69.27; H, 8.36; N, 5.05%].

Note The following reactions involving azetidines were performed on pure cis or trans isomers. A single procedure followed by the individual yields and analytical data is given where applicable.

2-(Carboxylic acid t-butyl ester)-4-hydroxymethylazetidide (13).

A solution of crude trans-12 (12.5 g, 45.1 mmol) in methanol (10 ml) was hydrogenated over 10% palladium on carbon (0.70 g) until the required amount of hydrogen (ca 1090 ml) was consumed (ca 4 hours). The catalyst was removed by filtration (celite) and the filtrate evaporated to dryness. The residue was then recrystallised (ether/hexane) to give trans-13 as colourless prisms (7.6 g, 90%). m.p. 64-66°C; ν_{\max} (KBr disc) 3305 s, 3240 b, 1733 s, 1400 m, 1369 s, 1230 s, 1160 s, 1105 s, 1034 s, 839 s and 770 m cm^{-1} ; δ_{H} 1.41(9H, s, t-Bu), 2.16-2.29(1H, m, 3-H), 2.36-2.50(1H, m, 3-H), 3.30(2H, b, OH), 3.42(1H, dd, J 12, 4Hz, CH_2O), 3.51(1H, dd, J 12, 3.5Hz, CH_2O), 3.80-3.93 (1H, m, 4-H), 4.19(1H, dd, J 9, 7.5Hz, 2-H); δ_{C} 26.4(t, 3-C), 27.9(q, CCH_3), 55.3(d, CN) 57.2(d, CN), 64.8(t, CH_2O), 81.3(CCH_3), 174.4(s, CO); m/e (E.I.) 188(6, $\text{M}^+ + 1$), 91(100) [Found C, 57.45; H, 9.08; N, 7.41. $\text{C}_8\text{H}_{15}\text{NO}_4$ requires C, 57.73; H, 9.15; N, 7.48%]. For trans-13: Yield [636 mg, 93% from trans-12 (1.01 g, 3.65 mmol)]. m.p. 80-81°C (from ether, hexane); ν_{\max} (KBr disc) 3320 m, 3165 b, 1725 s, 1372 m, 1317 s, 1237 s, 1163 s, 1070 s and 950 m cm^{-1} ; δ_{H} 1.46(9H, s, t-Bu), 2.01-2.22(1H, m, 3-H), 2.43-2.65(1H, m, 3-H), 3.46(1H, dd, J 11.5, 5Hz, CH_2O), 3.51 (1H, dd, J 11.5, 3Hz, CH_2O), 3.38-3.73(2H, b, NH, OH), 3.87(1H, dd, J 9.5, 4Hz, 2-H), 3.93-5.03(1H, m, 4-H); m/e (NH_3 , C.I.) 188(100, $\text{M}^+ + 1$), 132 (35), 86(25); [Found C, 57.80; H, 9.06; N, 7.73. $\text{C}_8\text{H}_{15}\text{NO}_4$ requires C, 57.73; H, 9.15; N, 7.48%].

N-(Benzyloxycarbonyl)-2-(carboxylic acid t-butyl ester)-4-(hydroxymethyl)azetidide (14).

To a solution of trans-13 (9.63 g, 51.5 mmol) in dichloromethane (100 ml) and benzyl chloroformate (85% w/w, 9.79 g, 48.9 mmol) at 0°C was added pyridine (3.90 g, 51.5 mmol). The solution was allowed to warm to room temperature and was stirred for 1 hour. Work up as described for the preparation of 11, followed by chromatography [flash silica, ether:hexane (0:1-1:0)] and crystallisation (ether/hexane) gave trans-14 (15.8 g, 91%); m.p. 51-53°C (from ether); t.l.c. (ether) Rf 0.6; ν_{\max} (film) 3480 b, 1735 s, 1714 s, 1690 s, 1425 s, 1365 s, 1150 m, 1090 m and 770 m cm^{-1} ; δ_{H} (showed rotational isomers in a ca 4:1 ratio, only the major is described) 1.39(9H, s, t-Bu), 2.08-2.20(1H, m, 3-H), 2.24-2.38(1H, m, 3-H), 3.57-3.88(3H, m, CH_2OH), 4.40(1H, dd, J 9.5, 4Hz, 2-H), 4.61-4.73(1H, bm, 4-H), 5.08, 5.15 (2H, ABq, J 12.5Hz, CH_2Ph), 7.15-7.25(5H, m, Ph); δ_{C} 23.3(t, 3-C), 27.8(q, CH_3), 59.5(d), 62.6(d), 65.7(t, CH_2OH), 67.1(t, CH_2Ph), 81.9(s, CCH_3), 127.9, 128.1, 128.4(3 x d, Ph), 135.9(s, Ph), 156.6(s, CO), 170.0(s, CO); m/e (NH_3 , D.C.I.) 339(15, $\text{M}^+ + \text{NH}_4^+$), 322(100, $\text{M}^+ + 1$), 266(30), 220(42), 91(28); [Found C, 63.62; H, 7.01; N, 4.24. $\text{C}_{14}\text{H}_{23}\text{NO}_6$ requires C, 63.54; H, 7.21; N, 4.36%]. For cis-14: Yield [9.20 g, 88% from cis-13 (6.10 g, 32.6 mmol)]; as a colourless oil [purified by chromatography (flash silica, ether:hexane (0:1-1:0))]; t.l.c. (ether) Rf 0.6; ν_{\max} (film) 3450 b, 1740 s, 1700 s, 1415 m, 1350 m and 1160 s cm^{-1} ; δ_{H} 1.42(9H, s, t-Bu), 2.03-2.39(1H, bm, 3-H), 2.54(1H, ca dt, J 11.5, 9Hz, 3-H), 3.73(2H, bm, CH_2OH), 3.88(1H, bd, OH), 4.45-4.47(1H, bm, 4-H), 4.49(1H, dd, J 9.5, 6Hz, 2-H), 5.02, 5.11(2H, ABq, J 12.5Hz, CH_2Ph), 7.25-7.43(5H, m, Ph); δ_{C} 22.5(t, 3-C), 27.5(q, CH_3), 58.0(d), 61.3(d), 63.7(t, CH_2OH), 66.6(t, CH_2Ph), 81.7(s, CCH_3), 127.4, 127.7, 128.1(3 x d, Ph), 135.8(s, Ph), 155.6(s, CO), 170.1(s, CO); m/e (NH_3 , D.C.I.) 339(10, $\text{M}^+ + \text{NH}_4^+$), 322(100, $\text{M}^+ + 1$), 266(35), 220(25), 91(20); [Found C, 63.41; H, 6.99; N, 4.52. $\text{C}_{14}\text{H}_{23}\text{NO}_6$ requires C, 63.54; H, 7.21; N, 4.36%].

N-(Benzyloxycarbonyl)-2-(carboxylic acid t-butyl ester)-4-(formyl)azetidide (15).

Alcohol (cis-14) (3.90 g, 12.1 mmol) and dicyclohexylcarbodiimide (7.57 g, 36.6 mmol) were dissolved in benzene (100 ml) containing dimethyl sulphoxide (21 ml) and pyridine (438 mg, 6.10 mmol). The solution was cooled to 0°C and trifluoroacetic acid (695 mg, 6.10 mmol) was added dropwise. After stirring for 30 minutes at 0°C and for 3 hours at 20°C, water (50 ml) was added and the reaction mixture stirred for a further 1 hour at 20°C. The solution was filtered (celite), washed with ether, the organic layer separated, dried and kept at -30°C for 15 hours. After filtration (celite) and evaporation the residue was chromatographed [flash silica (ether)] to give cis-15 (2.92 g, 75%). The ^1H NMR spectra of both cis-15 and trans-15 were broad, complex and indicated less than 50% of the free aldehyde was present. These aldehydes polymerised on standing, however, even after prolonged storage they reacted as the free aldehydes. For cis-15: δ_{H} (only major resonances are reported) 1.38, 1.45(9H, 2 x s, t-Bu), 2.00-2.59(2H, m, 3-H), 4.42(ca 1H, dd, J 9, 4Hz, 2-H), 4.33-4.71(ca 1H, m, 4-H), 5.01, 5.03(2H, ABq, J 12.5Hz, CH_2Ph), 7.28-7.34(5H, m, Ph), 9.8(ca 0.3H, s, CHO). For trans-15: Yield [1.93 g, 78% from trans-14 (2.02 g, 7.73 mmol)]; δ_{H} 1.33(9H, s, t-Bu), 2.11-2.68 (2H, m, 3-H), 4.40-4.51(2H, m, 2-H, 4-H), 5.02-5.12(2H, m, CH_2Ph), 7.19-7.23(5H, m, Ph), 9.85(ca 0.5H, s, CHO).

N-(Benzyloxycarbonyl)-2-(carboxylic acid t-butyl ester)-4-(3-propenoic acid p-nitrobenzyl ester) azetidines (16).

To a solution of trans-15 (7.10 g, 22.3 mmol) in dichloromethane (40 ml) was added a solution of triphenylphosphoranylidene(acetic acid)p-nitrobenzyl ester¹⁸ (10.2 g, 22.3 mmol) in dichloromethane (20 ml). The solution was left to stand overnight, then was evaporated to dryness and the residue chromatographed [flash silica, ether/hexane (0:1-1:0)] to give trans-16 (10.3 g, 93%) as a colourless oil (E:Z, > 10:1). For E-trans-16: t.l.c. (ether) Rf 0.45; ν_{\max} (film) 1739 s, 1723 s, 1716 s, 1523 s, 1350 s, 1158 s, 853 s, 748 m and 700 w cm^{-1} ; δH (showed rotational isomers in a ca 1:1 ratio) 1.37, 1.45(9H, 2 x s, t-Bu), 2.35(2H, b, ca t, 3-H), 4.45(1H, b, ca t, 2-H), 5.01-5.23(1H, m, 4-H), 5.05-5.07(2H, m, CH_2Ar), 5.23-5.25(2H, m, CH_2Ar), 6.04, 6.12(1H, 2 x d, J 16, 15.5Hz, C=CHCO), 7.09, 7.10(1H, 2 x dd, J 16, 5.5Hz and J 15.5, 5.5Hz, CH=CO), 7.18-7.37(5H, m, Ph), 7.50(2H, d, J 8.5Hz, ArNO_2), 8.17(2H, d, J 8.5Hz, ArNO_2); 6C 27.9(q, CH_3), 27.9(t, 3-C), 58.9(d) and 59.6(d) (2-C and 4-C), 64.8(t) and 67.1(t) (2 x CH_2Ar), 82.2(s, CCH_3), 121.2(d, C=CCO), 123.7(d, ArNO_2), 127.9, 128.0, 128.1(3 x d, Ph), 128.1(d, ArNO_2), 136.5(s, Ph), 143.0(s, ArNO_2), 146.9(d, C=CCO), 148.1(s, ArNO_2), 153.0(s, CO), 165.4(s, CO), 170.0(s, CO); m/e (NH_3 , D.C.I.) 514(2, $\text{M}+\text{NH}_4^+$), 497(5, M^+1), 458(22), 441(10), 400(30), 323(50), 306(60), 122(80), 91(100); [Found C, 63.04; H, 5.62; N, 5.81. $\text{C}_{26}\text{H}_{28}\text{N}_2\text{O}_8$ requires C, 62.90; H, 5.68; N, 5.64]. For cis-16: Yield 1.39 g, 93% from cis-15 (970 mg, 3.04 mmol). A ca 1:1 mixture of E:Z isomers was obtained. A small sample was separated for analytical purposes. For Z-cis-16: m.p. 72-74°C (from ether/hexane); ν_{\max} (KBr disc) 1739 s, 1723 s, 1703 s, 1520 s, 1420 m, 1347 s, 1160 s, 842 m, 812 m, 768 m, 741 m and 701 m cm^{-1} ; δH 1.43(9H, s, t-Bu), 1.94(1H, ca dt, J 12, 5.5Hz, 3-H), 2.98(1H, ca dt, J 12, 5.5Hz, 3-H), 4.30(1H, dd, J 9, 5.5Hz, 2-H), 5.07, 5.11(2H, ABq, J 12.5Hz, CH_2Ar), 5.21(2H, s, CH_2Ar), 5.53-5.63(1H, m, 4-H), 5.91(1H, dd, J 11.5, 1.5Hz, CH=CHCO), 6.72(1H, dd, J 11.5, 6.5Hz, CH=CHCO), 7.27-7.35(5H, s, Ph), 7.49(2H, d, J 8.5Hz, ArNO_2), 8.21(2H, d, J 8.5Hz, ArNO_2); m/e (NH_3 , D.C.I.) 514(23, $\text{M}+\text{NH}_4^+$), 497(3, M^+1), 458(100), 441(27), 323(31), 306(15), 122(20), 108(35), 91(38); [Found C, 63.19; H, 5.48; N, 5.45. $\text{C}_{26}\text{H}_{28}\text{N}_2\text{O}_8$ requires C, 62.90; H, 5.68; N, 5.64]. For E-cis-16, m.p. 95.5-97.5°C (from ether/hexane); ν_{\max} (KBr disc) 1736 s, 1723 s, 1714 s, 1501 s, 1414 s, 1314 s, 1159 s, 852 m, 731 m and 695 m cm^{-1} ; δH 1.44(9H, s, t-Bu), 2.05(1H, ca dt, J 11.5, 6Hz, 3-H), 4.56(1H, dd, J 9, 6Hz, 2-H), 4.80-4.88(1H, m, 4-H), 5.10, 5.14(2H, ABq, J 12.5Hz, CH_2Ar), 5.28(2H, s, CH_2Ar), 6.25(1H, dd, J 15.5, 1.5Hz, CH=CHCO), 7.14(1H, dd, J 15.5, 6Hz, CH=CHCO), 7.31(5H, s, Ph), 7.53(2H, d, J 9Hz, ArNO_2), 8.22(2H, d, J 9Hz, ArNO_2); m/e (NH_3 , D.C.I.) 497(5, M^+1), 458(22), 441(18), 323(18), 306(15), 122(100), 108(58), 91(53); [Found C, 62.87; H, 5.58; N, 5.59. $\text{C}_{26}\text{H}_{28}\text{N}_2\text{O}_8$ requires C, 62.90; H, 5.68; N, 5.64].

N-(Benzyloxycarbonyl)-2-(carboxylic acid t-butyl ester)-4-(3-propenoic acid p-nitrobenzyl ester) azetidines (17).

A solution of cis-16 (12.2 g, 24.6 mmol) in benzene (120 ml) containing tris-triphenylphosphine rhodium chloride (1.2 g, 1.3 mmol) was hydrogenated until the required amount of hydrogen was consumed (3-16 hours). The solvent was removed *in vacuo* and the residue dissolved in ether (50 ml) and allowed to stand for 2 hours. The solution was then filtered (celite) and evaporated to dryness. The residue was chromatographed [flash silica, ether/hexane (0:1-1:0)] to give cis-17 (11.8 g, 96%). m.p. 80-81°C (from ether); t.l.c. (ether/hexane, 1:1) Rf 0.3; ν_{\max} (CHCl_3) 1748 s, 1739 s, 1705 s, 1600 s, 1515 s, 1345 s, 1177 s, 835 m, 765 m and 732 m cm^{-1} ; δH 1.44(9H, s, t-Bu), 1.85-1.93(1H, m, CH_2), 2.06-2.29(1H, m, CH_2), 2.58-2.67(3H, m, CH_2), 4.27-4.34(1H, m, 4-H), 4.49(1H, dd, J 9.5, 6Hz, 2-H), 5.07, 5.13(2H, ABq, J 12.5Hz, CH_2Ar), 5.19(2H, s, CH_2Ar), 7.28-7.33(5H, m, Ph), 7.50(2H, d, J 8.5Hz, ArNO_2), 8.21(2H, d, J 8.5Hz, ArNO_2); 6C 26.7(t, $\text{CH}_2\text{CH}_2\text{CO}$), 27.9(q, CH_3), 29.9(t, 3-C), 30.6(t, CH_2CO_2), 58.5(d), 59.2(d) (2-C, 4-C), 64.7(t, CH_2Ar), 66.8(t, CH_2Ar), 123.7(d, ArNO_2), 127.7, 128.0, 128.2, 128.4(4 x d, Ar), 136.6(s, Ph), 143.3(s, ArNO_2), 147.6(s, ArNO_2), 156.3(s, CO), 170.2(s, CO), 172.6(s, CO); m/e (NH_3 , D.C.I.) 516(40, $\text{M}+\text{NH}_4^+$), 499(10, M^+1), 460(60), 443(100), 353(35), 303(36), 91(90). [Found C, 62.91; H, 5.94; N, 5.61. $\text{C}_{26}\text{H}_{28}\text{N}_2\text{O}_8$ requires C, 62.64; H, 6.07; N, 5.62]. For trans-17: Yield [5.01 g, 92% from trans-16 (5.41 g, 10.9 mmol)]; m.p. 46-51°C (from ether); ν_{\max} (film) 1740 s, 1715 s, 1522 m, 1345 s, 1155 s, 849 m and 739 m cm^{-1} ; δH (showed rotational isomers in a ca 1:1 ratio) 1.37, 1.45(9H, 2 x s, t-Bu), 1.99-2.13(1H, m, CH_2), 2.14-2.34(3H, m, CH_2), 2.43(1H, ca t, CH_2), 2.58(1H, ca t, CH_2), 4.42(1H, dd, J 8.5, 5.5Hz, 2-H), 4.45-4.53(1H, m, 4-H), 5.06(2H, s, CH_2Ar), 5.10-5.28(2H, m, CH_2Ar), 7.23-7.40(5H, m, Ph), 7.50(2H, d, J 8.5Hz, ArNO_2), 8.20(2H, d, J 8.5Hz, ArNO_2); m/e (NH_3 , D.C.I.) 516(1, $\text{M}+\text{NH}_4^+$), 499(5, M^+1), 460(1), 230(40), 122(60), 91(100). [Found C, 62.85; H, 5.98; N, 5.28. $\text{C}_{26}\text{H}_{28}\text{N}_2\text{O}_8$ requires C, 62.64; H, 6.07; N, 5.62].

2-(Carboxylic acid t-butyl ester)-4-(3-propenoic acid)azetidines (18).

A solution of trans-17 (1.40 g, 2.81 mmol) in methanol (20 ml) was hydrogenated over 10% palladium on charcoal (200 mg) at 20°C until the required amount of hydrogen (ca 340 ml) was absorbed (2-4 hours). The catalyst was removed (filtration, celite) and the filtrate evaporated to dryness. The residue was titrated with ether until a precipitate formed. The solid was then recrystallised (methanol/ether) to give trans-18 (560 mg, 87%); m.p. 111-113°C (from methanol/ether); ν_{\max} (KBr disc) 3425 b(OH), 2655 b, 2470 b, 1743 s, 1740 s, 1602 m, 1554 s, 1259 s, 1165 s and 1018 m cm^{-1} ; δH 1.46(9H, s, t-Bu), 1.91-2.60(6H, m, CH_2), 4.20-4.23(1H, m, 4-H), 4.31(1H, dd, J 9.5, 6Hz, 2-H); m/e (NH_3 , D.C.I.) 230(1, M^+1), 174(3), 128(100), 85(55). [Found C, 57.21; H, 8.45; N, 6.31. $\text{C}_{11}\text{H}_{13}\text{NO}_4$ requires C, 57.63; H, 8.65; N, 6.11]. For cis-18: Yield [2.7 g, 97% from cis-17 (5.73 g, 11.5 mmol)]; m.p. 134-136°C (from methanol/ether); ν_{\max} (KBr, disc) 1747 s, 1739 s, 1704 s, 1515 m, 1416 s, 1408 s, 1345 s, 1256 s, 1155 s, 832 m, 765 m, 731 s and 697 m cm^{-1} ; δH 1.46(9H, s, t-Bu), 1.75-1.88(1H, m, CH_2), 2.07-2.29(3H, m, CH_2), 2.39-2.42(1H, m, CH_2), 2.80-2.85(1H, m, CH_2), 4.23-4.27(1H, m, 4-H), 4.63(1H, dd, J 9.5, 8Hz, 2-H); m/e (NH_3 , D.C.I.) 230(100, M^+1), 174(10), 128(10). [Found C, 57.30; H, 8.54; N, 5.91. $\text{C}_{11}\text{H}_{13}\text{NO}_4$ requires C, 57.63; H, 8.65; N, 6.11].

t-Butyl-2-oxo-1-azabicyclo[3.2.0]heptane-7-exo-carboxylate (exo-19) and t-Butyl-2-oxo-1-azabicyclo[3.2.0]heptane-7-endo-carboxylate (endo-19).

To a solution of trans-18 (689 mg, 3.01 mmol) in acetonitrile (40 ml) were added 2,2'-dipyridyldisulphide (729 mg, 3.31 mmol) and triphenylphosphine (868 mg, 3.31 mmol). The solution was stirred for 3h at 20°C and then evaporated to dryness. The residue was dissolved in ether (20ml), filtered, evaporated to dryness and chromatographed (flash silica, ether) to give exo-19 (575 mg, 91%); m.p. 73.5-74.5°C (prisms from ether); t.l.c. (ether) Rf 0.6; ν_{\max} (KBr disc) 1740 s, 1694 s, 1362 s, 1277 m, 1239 s, 1168 s, 1104 s, 976 m and 853 cm^{-1} ; δ_{H} 1.48(9H, s, t-Bu), 1.98-2.14(1H, m, 4-H), 2.26(1H, ddd, J 16, 9, 1Hz, 3-H), 2.39-2.45(1H, m, 4-H), 2.53-2.74(3H, m, 3-H, 2 x 6-H), 4.48(1H, dd, J 9.5, 4.5Hz, 7-H), 4.51-4.55(1H, m, 5-H). A 2D-COSY spectrum was consistent with the connectivity as specified; δ_{C} 27.9(q, CH₂), 30.9(t), 32.1(t) (4-C, 6-C), 35.5(t, 3-C), 59.9(d), 61.5(d) (5-C, 7-C), 82.0(s, CCH₂), 170.3(s, CO), 183.8(s, CO); m/e (E.I.) 211(2, M⁺), 155(15), 110(100); 57(80); [Found C, 62.77; H, 7.80; N, 6.73. C₁₁H₁₇NO₂ requires C, 62.54; H, 8.11; N, 6.63%]. For endo-19: Yield [254 mg, 75% from cis-18 (368 mg, 1.61 mmol)]; m.p. 75.0-75.5°C (prisms from ether). t.l.c. (ether) Rf 0.6; ν_{\max} (KBr disc) 1736 s, 1704 s, 1372 s, 1279 s, 1238 s, 1158 s, 1120 m and 848 cm^{-1} ; δ_{H} 1.49(9H, s, t-Bu), 2.22-2.55(5H, m, CH₂), 2.75(1H, ca dt J 11.5, 7.5Hz, 6-H), 4.26-4.32(1H, m, J 7.5Hz, 5-H), 4.60(1H, ca t, J 7Hz, 7-H); A 2D-COSY spectrum was consistent with the connectivity as specified; δ_{C} 27.7(q, CH₂), 31.5(t), 31.7(t) (4-C, 6-C), 32.6(t, 3-C), 58.7(d), 62.6(d) (5-C, 7-C), 82.2(s, CCH₂), 177.7(s, CO), 182.9(s, CO); m/e (E.I.) 211(2, M⁺), 155(18), 110(100), 57(95); [Found C, 62.36; H, 7.91; N, 6.81. C₁₁H₁₇NO₂ requires C, 62.54; H, 8.11; N, 6.63%].

t-Butyl-3-endo-amino-2-oxo-1-azabicyclo[3.2.0]heptane-7-exo-carboxylate (21).

To a solution of exo-19 (79 mg, 0.37 mmol) in tetrahydrofuran (1.5 ml) was added a solution of lithium bis(trimethylsilyl)amide in tetrahydrofuran (1.0 molar, 0.41 mmol). After stirring for 1 hour at -70°C, O-(diphenylphosphinoyl)hydroxylamine (96 mg, 0.41 mmol) was added. The suspension was stirred at -70°C for a further 3 hours, then allowed to warm to 20°C overnight, after which it was quenched with 1N hydrochloric acid (5 ml). The tetrahydrofuran was removed *in vacuo* and the aqueous solution extracted with ether (10 ml), basified to pH 10 with 5N potassium hydroxide and extracted with ethyl acetate (3 x 15 ml). The organic solution was dried and evaporated to dryness to give 21 (40 mg, 47%) (>90% pure). The ethereal washings were dried, evaporated to dryness and the residue chromatographed (P.L.C., ether) to give (25 mg, 30%) recovered starting material (exo-19). For 21: ν_{\max} (CHCl₃) 3450 m, 3390 m, 1740 bs and 1520 cm^{-1} ; δ_{H} 1.49(9H, s, t-Bu), 1.69-1.88(1H, m, 4-H), 2.02-2.54(2H, b, NH₂), 2.56-2.73(2H, m, 6-H), 2.78-2.87(1H, m, 4-H), 3.81(1H, dd, J 12.5, 8Hz, 3-H), 4.44-4.50(1H, m, 5-H), 4.59(1H, dd, J 9.5, 4.5Hz, 7-H); m/e (NH₃, D.C.I.), 453(2M⁺+1), 227(80, M⁺+1), 171(100), 156(60).

t-Butyl-3-endo-phenoxyacetamido-2-oxo-1-azabicyclo[3.2.0]heptane-7-exo-carboxylate (22).

To a solution of 21 (75 mg, 0.33 mmol) in dichloromethane (5 ml) was added phenoxyacetic acid (51 mg, 0.33 mmol), 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (99 mg, 0.40 mmol) and sodium sulphate (ca 5 mg). After stirring for 24 hours, work up as for 11, followed by chromatography (P.L.C., ether) gave 22 (95.4 mg, 85%); m.p. 104-105°C (prisms from ether/hexane); t.l.c. (ether) Rf 0.4; ν_{\max} (KBr disc) 1747 s, 1705 s, 1700 (shoulder), 1565 s, 1525 s, 1288 s, 1233 s, 1157 m, 1108 m and 751 cm^{-1} ; δ_{H} 1.51(9H, s, t-Bu), 1.94(1H, ca dt, J 12, 8Hz, 4-H), 2.60-2.79(2H, m, 6-H), 3.13-3.18(1H, m, 4-H), 4.51(2H, s, CH₂O), 4.54-4.63(1H, obscured by CH₂O, 3-H), 4.62(1H, dd, J 9.5, 4.5Hz, 7-H), 4.59-4.66(1H, m, 5-H), 6.94-7.10(3H, m, Ar), 7.24(1H, bd, J 5.5Hz, NH), 7.26-7.36(2H, m, Ar); A 2D-COSY experiment was consistent with the connectivity as specified; m/e (NH₃, D.C.I.) 361(82, M⁺+1), 305(100), 304(41), 259(12), 152(9), 80(28), 57(24). [Found C, 63.45; H, 6.51; N, 7.43. C₁₇H₂₄N₂O₃ requires C, 63.32; H, 6.71; N, 7.77%].

1-Azabicyclo[3.2.0]heptane-7-exo-carboxylate (exo-23) and 1-Azabicyclo[3.2.0]heptane-7-endo-carboxylate (endo-23).

The ester (exo-19) (20 mg, 9.5×10^{-2} mmol) was dissolved in freshly distilled trifluoroacetic acid (0.25 ml) and allowed to stand at room temperature for 15 minutes. The excess acid was removed *in vacuo* to give a gum which was titrated with ether until precipitation occurred to give exo-23 (12.5 mg, 83%). m.p. 134.0-134.5°C (from dichloromethane/ether); ν_{\max} (KBr disc) 3100-2800 b, 2715 m, 2590 m, 1745 s, 1665 s, 1365 s, 1280 m, 1200 s and 1105 cm^{-1} ; δ_{H} 2.03-2.21(1H, m, 4-H), 2.33-2.36(1H, m, 4-H), 2.44-2.53(1H, m, CH₂), 2.63-2.84(3H, m, CH₂), 4.54-4.63(1H, m, 5-H), 4.70(1H, dd, J 10, 4.5Hz, 7-H), 9.24(1H, s, CO₂H); m/e (E.I.) 155(10, M⁺), 110(6), 84(22), 82(20). [Found 155.0583. C₇H₉NO₂ requires 155.0582]. For endo-23: Yield [8.8 mg, 80% from endo-19 (15 mg, 7.1×10^{-2} mmol)]; m.p. 107-110°C (from dichloromethane/ether); ν_{\max} (KBr disc) 3100-2820 b, 2700 m, 2580 m, 1738 s; δ_{H} 2.26-2.61(5H, m, CH₂), 2.82(1H, ca dt, J 11.5, 7.5Hz, 6-H), 4.33-4.39(1H, m, 5-H), 4.81(1H, ca t, J 7.5Hz, 7-H), 11.53(1H, s, CO₂H); m/e (E.I.) 155(10, M⁺), 127(6), 111(17), 110(100). [Found 155.0583. C₇H₉NO₂ requires 155.0582].

3-Endo-phenoxyacetamido-2-oxo-1-azabicyclo[3.2.0]heptane-7-exo-carboxylate (26).

The ester (22) (11 mg, 3.1×10^{-2} mmol) was dissolved in freshly distilled trifluoroacetic acid (0.1 ml) and allowed to stand at room temperature for 15 minutes. The acid was removed *in vacuo* and the residue titrated with dichloromethane until precipitation occurred. The solvent was decanted to give the free acid which was dissolved in deuterated pH 7.6, 50 molar, K₂HPO₄-KH₂PO₄-KCl buffer to give 26; δ_{H} 2.08-2.22(1H, m, 4-H), 2.54-2.83(3H, m, 4-H, 6-H), 4.37-4.49(1H, m, 5-H), 4.56(2H, s, CH₂O), 4.59-4.70(1H, m, 3-H), 4.75(1H, dd, J 14, 8Hz, 7-H), 6.38-7.28(5H, m, Ar); m/e (NH₃, C.I.) 305(10, M⁺+1). 26 was stable in the buffered solution for greater than 18 hours (by ¹H NMR, 300MHz). After which the solution was evaporated to dryness and the residue was resuspended in acetone (1ml). Methyl iodide (0.1ml), triethylamine (10 μ l, 3.6×10^{-2} mmol) and sodium sulphate (ca 5mg) were added. The reaction mixture was stirred for 6 hours at 20°C, when work up, as for the preparation of 11, followed by chromatography (P.L.C., ether) gave 29 as a colourless oil (2.3mg, 23%, unoptimised): t.l.c. (ether) Rf 0.4; δ_{H} 1.88-1.98(1H, m, 4-H), 2.60-2.75(2H, m, 6-H), 3.10-3.17(1H, m, 4-H), 3.84(3H, s, CH₃), 4.53(2H, s, CH₂O), 4.52-4.58(1H, m, 3-H), 4.62(1H, dd, J 9.5, 5Hz, 7-H), 4.60-4.65(1H, m, 5-H), 6.94-7.10(3H, m, Ar), 7.30(1H, bd, J 5.5Hz, NH), 7.26-7.33(2H, m, Ar); m/e (NH₃, D.C.I.) 319(74, M⁺+1), 259(s, M⁺-CO₂CH₃).

Methyl-2-oxo-1-azabicyclo[3.2.0]heptane-7-exo-carboxylate (exo-27) and Methyl-2-oxo-1-azabicyclo[3.2.0]heptane-7-endo-carboxylate (endo-27).

Endo-19 (15mg, 7.1×10^{-2} mmol) was dissolved in freshly distilled trifluoroacetic acid (0.2 ml) and allowed to stand at room temperature for 15 minutes. The acid was removed in vacuo and the residue dissolved in pH 7.6, 50 mmolar, phosphate buffer (K_2HPO_4 - KH_2PO_4 -KCl). After 12 hours the solution was evaporated to dryness. The residue was re-suspended in acetone (1 ml) and methyl iodide (0.1 ml), triethylamine (19.8 μ l, 7.2×10^{-2} mmol) and sodium sulphate (ca 5 mg) were added. The reaction mixture was stirred for 2 hours at 20°C, after which work up, as for the preparation of 11, followed by chromatography (P.L.C., ether) gave endo-27 as a colourless oil (8.8 mg, 73%); t.l.c. (ether) Rf 0.35; ν_{max} (CHCl₃) 1743 s, 1705 s, 1475 s and 1135 m cm⁻¹; δ_H 2.23-2.58(5H, m, CH₂), 2.80(1H, ca dt, J 11.5, 7.5Hz, 6-H), 3.80(3H, s, CH₃), 4.31-4.37(1H, m, 5-H), 4.76(1H, bt, J 7Hz, 7-H); m/e (I.B.E.I.) 170(4, M⁺+1), 169(12, M⁺), 110(18), 82(100); [Found 169.0738. C₈H₁₁NO, requires 169.0739]. For exo-27: Yield [2 mg, 30%] from exo-19 (8 mg, 3.8×10^{-2} mmol); ν_{max} (CHCl₃) 1745 s, 1702 s, 1470 s and 1032 s cm⁻¹; δ_H 1.99-2.60(6H, m, CH₂), 3.79(3H, s, CH₃), 4.57(1H, dd, J 9.5, 4.5Hz, 7-H), 4.60-4.65(1H, m, 5-H); m/e (NH₃, C.I.) 170(100, M⁺+1), 110(22). [Found 169.0738. C₈H₁₁NO, requires 169.0739].

Biological testing

The carboxylate salts exo-25, endo-25 and 26 were tested for antibacterial activity, using ampicillin as a standard of known activity, against a panel of 33 cultures in minimal nutrient agar. All were found to be biologically inactive up to a concentration of 0.1mg/ml in pH 7.6, 50 mmolar phosphate buffer (KH_2PO_4 - K_2HPO_4 -KCl). The panel consisted of: Gram positive bacteria [Staphylococcus aureus, strains (222, 223, 267, 268⁻¹, 268⁻², 450, 451, 43, Sarcina lutea, Bacillus subtilis, Bacillus cereus, Streptomyces pyogenes, Commons ter.]; Gram negative bacteria [Escherichia coli, strains (116, 146, 172, 198, 603⁻¹, 603⁻², 604, 605, 606, 607, 608), Enterobacter (2.7.11), Klebsiella aerogenas, strains (37, 54, 175), Pseudomonas aeruginosa, strains (56, 433, 434)] and a fungus (Candida).

Crystal data for (endo-19) C₈H₁₁NO₃, M= 211.16, orthorhombic, space group Pbc_a, a= 10.775(3), b= 11.164(2), c= 18.807(3) Å, U= 2262.3 Å³, Z= 8, D_c= 1.24 g cm⁻³. 1985 independent reflections were measured by four circle (CAD-4) diffractometry using Mo-K α radiation (λ = 0.71069 Å). The structure was solved by direct methods.¹⁹ 1387 Reflections [$I \geq 3\sigma(I)$] uncorrected for absorption¹⁹ [μ (Mo-K α)= 0.98 cm⁻¹] were used in a full matrix least squares²⁰ refinement for all atomic parameters including one overall temperature factor for the hydrogen atoms. Restraints²¹ were applied to the C-H bonds, and to the methyl H-C-H bond angles. The final R value was 0.072 (R_w= 0.074).

Crystal data for 22: C₁₁H₂₁N₂O₄, M= 360.41, monoclinic, space group P2₁/c, a= 15.487(2), b= 11.093(2), c= 11.931(1) Å, β = 112.42(1); U= 1894.7 Å³, Z= 4, D_c= 1.26 g cm⁻³. 4669 independent reflections were measured with an Enraf-Nonius CAD-4 diffractometer using Cu-K α radiation (λ = 1.5418 Å). The structure was solved by direct methods.¹⁹ 3296 Reflections [$I \geq 3\sigma(I)$] uncorrected for absorption [μ (Cu-K α)= 7.68 cm⁻¹] were used in a blocked least squares²⁰ refinement. All atomic parameters were included in the refinement, including positional parameters for the hydrogen atoms and one overall temperature factor for the hydrogen atoms. The final R value was 0.057 (R_w= 0.081).

Crystal data for cis-12: C₁₁H₂₁NO₃, M= 277.35, space group P2₁/n, a= 11.839(1), b= 9.638(5), c= 14.638(5) Å, U= 1593.0 Å³, Z= 4, D_c= 1.16 g cm⁻³. 3,791 Reflections were measured with an Enraf-Nonius CAD-4 diffractometer using Mo-K α radiation (λ = 0.71069 Å). The structure was solved by direct methods.¹⁹ 2046 Reflections [$I \geq 3\sigma(I)$] uncorrected for absorption [μ (Mo-K α)= 0.98 cm⁻¹] were used in a full matrix least squares refinement.²⁰ The final R value was 0.045 (R_w= 0.053).

Crystal data for (exo-19) C₁₁H₁₇NO₃, M= 211.16, space group P2₁/a, a= 10.058(2), b= 10.052(1), c= 11.604(1) Å, U= 1131.6 Å³, Z= 4, D_c= 1.24 g cm⁻³. 2326 Reflections were measured with an Enraf-Nonius CAD-4 diffractometer using Cu-K α radiation (λ = 1.5418 Å). The structure was solved by direct methods.¹⁹ 1900 Reflections [$I \geq 3\sigma(I)$] uncorrected for absorption were used in a blocked least squares refinement.²⁰ The final R value was 0.055 (R_w= 0.073).

The atomic co-ordinates for this work are available on request from the Director of the Cambridge Crystallographic Data Centre, University Chemical Laboratory, Lensfield Road, Cambridge, CB2 1EW.

ACKNOWLEDGEMENTS: We thank Dr. H-H. Ting, Dyson Perrins Laboratory for the β -lactamase inhibitory tests, Pfizer Central Research, Sandwich, Kent for support (to C.Z.) and the S.E.R.C. and Pfizer for C.A.S.E. support (to C.S.).

References

1. Part of this work has been published in a preliminary form: J.E. Baldwin, R.M. Adlington, R.H. Jones, C.J. Schofield, C. Zaracostas and C.W. Greengrass, J.Chem.Soc., Chem. Commun., 1985, 194.
2. R.B. Morin and M. Gorman (Ed.) 'Chemistry and Biology of Beta-Lactam Antibiotics', Academic Press, New York, 1982.
3. J.E. Baldwin, M.F. Chan, G. Gallacher, P. Monk and K. Prout, J.Chem.Soc., Chem.Commun., 1983, 250.
4. J.E. Baldwin, M.F. Chan, G. Gallacher, M. Otsuka, P. Monk and K. Prout, Tetrahedron, 1984, 40, 4513.
5. R.M. Sweet and L.F. Dahl, J.Amer.Chem.Soc., 1970, 92, 5489.
6. R.B. Woodward, Philos.Trans. R.Soc.London, Ser. B., 1980, 239. See also M.I. Page, Acc. Chem. Res., 1984, 17, 144.
7. C.K. Ingold, J.Chem.Soc., 1921, 316.
8. R.K. Friedlina, Dolk.Acad.Nauk. S.S.S.R., 1969, 187, 554.
9. M.F. Ansell in 'The Chemistry of the Acyl Halides', S. Patai (Ed.), Interscience Publishers Inc., London, 1972, pp. 44-46.
10. R.M. Rodenbaugh and N.H. Cromwell, J.Heterocycl.Chem., 1968, 5, 309.
11. I. Ojima, S. Suga and R. Abe, Chem.Lett., 1980, 853.
12. S. Kobayashi, T. Iimori, T. Izawa and M. Ohno, J.Amer.Chem.Soc., 1981, 103, 2406.
13. E.W. Colvin, G.W. Kirby and A.C. Wilson, Tetrahedron Lett., 1982, 23, 3835; G. Boche, M. Bernheim and W. Schrott, ibid., 1982, 23, 5399.
14. N.C. Cohen, J.Med.Chem., 1983, 26, 259.
15. U.S. Patent 4, 428, 960 (1984); Chem.Abstr., 1984, 100, 191655.
16. J.E. Baldwin, C. Lowe, C.J. Schofield and E. Lee, Tetrahedron Letts., submitted for publication. After completion of this work we were informed by Dr. L. Hatfield, Eli Lilly & Co., Indianapolis, USA, that they have prepared similar compounds.
17. J.E. Baldwin, E.P. Abraham, R.M. Adlington, M.J. Crimmin, L.D. Field, G.S. Jayatilake, R.L. White and J.J. Usher, Tetrahedron, 1984, 1907.
18. O. Osler, H. Gutman, M. Montavan, R. Riegg, G. Ryser and P. Zeller, Helv.Chim.Acta., 1957, 40, 1242.
19. P. Main *et al.*, 'MULTAN 80. A System of Computer Programs for the Automatic Solution of Crystal Structures from X-ray Diffraction Data', Department of Physics, University of York, 1980.
20. D.J. Watkin and J.R. Carruthers, 'Crystals User Guide', Chemical Crystallography Laboratory, University of Oxford, Oxford, 1981.
21. J. Waser, Acta Crystallogr., 1963, 16, 1091.